1. ALLA AKTIER
  2. NYHETER
  3. INTEGRUM

Integrum

Nyheter Integrum Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Integrum updates financial calendar following change of financial year

MARKN.

Mölndal, Sweden, October 15, 2026 – Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B) announces an updated financial calendar following the company's transition to a calendar year as its financial year.

The current financial year will end on December 31, 2026, meaning that the final reporting period, November–December 2026, will cover two months. From January 1, 2027, the company's financial reporting will follow the calendar year.

Updated financial calendar

EventDate
Year-end report 2026 (November–December 2026)February 11, 2027
Interim report Q1 2027May 13, 2027
Annual General Meeting 2027May 27, 2027
Half-year report Q2 2027August 26, 2027
Interim report Q3 2027November 11, 2027
Year-end report 2027February 10, 2028

The updated financial calendar will also be published on the company's website, www.integrum.se.

For further information, please contact:
Louise Wåhlin, CFO
Tel: +46 734 63 73 03
Email: louise.wahlin@integrum.se

Certified Adviser
DNB Carnegie Investment Bank AB (publ)
+46 8-588 685 70
certifiedadviser@dnbcarnegie.se

About Us
Integrum is a Swedish medical technology company developing solutions to improve mobility and quality of life for people living with limb loss. The company's OPRA™ Implant System is based on osseointegration, whereby a prosthesis is anchored directly to the skeleton without the need for a conventional socket. The system has been used to treat more than 1,000 patients worldwide and is certified under the EU Medical Device Regulation (MDR) and approved by the U.S. Food and Drug Administration (FDA). In parallel, Integrum is developing next-generation bionic solutions focused on intuitive prosthetic control and sensory feedback.
 
Integrum AB is listed on Nasdaq First North Growth Market (INTEG B). Learn more at www.integrum.se.

Attachments
Integrum updates financial calendar following change of financial year

Datum 2026-10-15, kl 08:00
Källa MFN
Bifogade filer
Integrum updates financial calendar following change of financial year